Medshine Discovery synthesizes new LRRK2 inhibitors
Oct. 19, 2022
Medshine Discovery Inc. has presented new pyrimidine derivatives acting as leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of neurodegeneration.